Business Context and Reporting Period
This Form 8-K is a current report filed by Neoleukin Therapeutics, Inc. (trading symbol: NLTX) on March 10, 2020. The registrant is incorporated in Delaware and maintains its principal executive offices in Seattle, Washington. The filing addresses corporate governance matters regarding the scheduling of the 2020 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on administrative and governance events rather than financial performance.
Material Changes
The primary material event reported is the scheduling of the 2020 Annual Meeting of Stockholders for May 5, 2020. This date is more than 30 days prior to the anniversary of the 2019 Annual Meeting, which was held on November 12, 2019. Consequently, the deadline for stockholders to submit qualified proposals or director nominations is March 20, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary on business outlook, financial guidance, or specific operational risks. The only contingency noted is the procedural requirement that any stockholder notice received after March 20, 2020, will be considered untimely and excluded from the 2020 Annual Meeting agenda.
Key Facts for Investor Verification
- Annual Meeting Date: May 5, 2020.
- Proposal Deadline: March 20, 2020, for qualified stockholder proposals or director nominations.
- Submission Address: Notices must be sent to the Secretary at 360-1616 Eastlake Avenue East, Seattle, Washington 98102.
- Financial Data: No financial metrics are disclosed in this specific filing.